General MedicationsORALGeneric
TAMIFLU
OSELTAMIVIR PHOSPHATE
Standard Dose
EQ 12MG BASE/ML
Max Dose
Refer to approved labeling
Primary Use
Review priority: N/A Marketing status: Discontinued
Summary
Approval overview TAMIFLU is listed in Drugs@FDA under application 021246 (NDA).
Review priority: N/A Marketing status: Discontinued Active ingredient OSELTAMIVIR PHOSPHATE Form and strength FOR SUSPENSION;ORAL - EQ 12MG BASE/ML Sponsor ROCHE Submission history Latest submission status date: 2021-08-10 00:00:00.
Structured Monograph
Clinical summary
Approval overview TAMIFLU is listed in Drugs@FDA under application 021246 (NDA). Review priority: N/A Marketing status: Discontinued Active ingredient OSELTAMIVIR PHOSPHATE Form and strength FOR SUSPENSION;ORAL - EQ 12MG BASE/ML Sponsor ROCHE Submission history Latest submission status date: 2021-08-10 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: N/A
Interaction Notes
- No interaction notes stored yet.